EORTC GUCG YI (@eortc_gucg_yeci) 's Twitter Profile
EORTC GUCG YI

@eortc_gucg_yeci

Young & Early Carreer Investigators @EORTC GU cancer group

ID: 1648996144368820224

calendar_today20-04-2023 10:25:03

61 Tweet

34 Followers

70 Following

Enrique Grande (@drenriquegrande) 's Twitter Profile Photo

⚡️ Updated Overall Survival by Circulating Tumor DNA Status from the Phase 3 IMvigor010 Trial: Adjuvant Atezolizumab Versus Observation in Muscle-invasive Urothelial Carcinoma #BladderCancer #Immunotherapy buff.ly/3O6YHxr

⚡️ Updated Overall Survival by Circulating Tumor DNA Status from the Phase 3 IMvigor010 Trial: Adjuvant Atezolizumab Versus Observation in Muscle-invasive Urothelial Carcinoma   

#BladderCancer #Immunotherapy

buff.ly/3O6YHxr
tombal (@bertrandtombal) 's Twitter Profile Photo

The other side of PSMA...A Case Series Study of the Role of Prostate-specific Membrane Antigen ... sciencedirect.com/science/articl…

Thomas Zilli (@zillithomas) 's Twitter Profile Photo

On y est presque!! Dans 11 jours on vous attend toutes/tous à la GFRU à Bordeaux pour le 5ème congrès international. Venez nombreux !! gfru.org/https-www-gfru…

On y est presque!! Dans 11 jours on vous attend toutes/tous à la GFRU à Bordeaux pour le 5ème congrès international. Venez nombreux !! gfru.org/https-www-gfru…
Guillaume Grs (@ggrisay) 's Twitter Profile Photo

Growing body of evidence suggests that patients with high-risk BCR should be managed with ARpI monotherapy. Side effects are manageable. the sooner the better ! Neil Shore Advanced Prostate Cancer Consensus Conference @APCCC24 OncoAlert

Growing body of evidence suggests that patients with high-risk BCR should be managed with ARpI monotherapy.  Side effects are manageable. the sooner the better ! Neil Shore <a href="/APCCC_Lugano/">Advanced Prostate Cancer Consensus Conference</a> @APCCC24 <a href="/OncoAlert/">OncoAlert</a>
Guillaume Grs (@ggrisay) 's Twitter Profile Photo

Now more than ever, it is important to propose de-escalation strategies. EORTC 2238 "De-Escalate" will address the specific question of intermittent therapy in these mHSPC patients ! tombal silke gillessen Fabio Turco Advanced Prostate Cancer Consensus Conference EORTC OncoAlert

Now more than ever, it is important to propose de-escalation strategies. EORTC 2238 "De-Escalate" will address the specific question of intermittent therapy in these mHSPC patients ! 
<a href="/BertrandTOMBAL/">tombal</a> <a href="/Silke_Gillessen/">silke gillessen</a> <a href="/fabioturco92/">Fabio Turco</a> <a href="/APCCC_Lugano/">Advanced Prostate Cancer Consensus Conference</a> <a href="/EORTC/">EORTC</a>  <a href="/OncoAlert/">OncoAlert</a>
EORTC GUCG YI (@eortc_gucg_yeci) 's Twitter Profile Photo

Nice talk by Dr Masson-Lecomte on the importance of defining the response to NAT, as well as the importance of multimodal assessment. Question will be answered by the EORTC2418 - ‘STARBURST’ study !#EORTC #EMUC24 Yohann Loriot Vérane Achard Julien Van Damme Guillaume Grs tombal

Nice talk by Dr Masson-Lecomte on the importance of defining the response to NAT, as well as the importance of multimodal assessment.  Question will be answered by the EORTC2418 - ‘STARBURST’ study !#EORTC #EMUC24 <a href="/y_loriot/">Yohann Loriot</a> <a href="/Achard_Verane/">Vérane Achard</a> <a href="/vandamme_jvd/">Julien Van Damme</a> <a href="/GGrisay/">Guillaume Grs</a> <a href="/BertrandTOMBAL/">tombal</a>
tombal (@bertrandtombal) 's Twitter Profile Photo

Fabio Turco⁩ presenting PEACE3 at EMUC, great efficacy and low toxicity of Radium in early mCRPC. The ideal therapy to layer on ARPI? Probably. ⁦EORTC⁩ ⁦silke gillessen⁩ ⁦EORTC GUCG YI

⁦<a href="/fabioturco92/">Fabio Turco</a>⁩ presenting PEACE3 at EMUC, great efficacy and low toxicity of Radium in early mCRPC. The ideal therapy to layer on ARPI? Probably. ⁦<a href="/EORTC/">EORTC</a>⁩ ⁦<a href="/Silke_Gillessen/">silke gillessen</a>⁩ ⁦<a href="/EORTC_GUCG_YECI/">EORTC GUCG YI</a>⁩
Fabio Turco (@fabioturco92) 's Twitter Profile Photo

Thank you very much tombal silke gillessen EORTC for this great opportunity! It was a privilege presenting PEACE 3 at #EMUC24 the first study (to date) to show a benefit in both rPFS and OS with ARPI combo in mCRPC. Remember the use of BPA in this setting!@OncoAlert

tombal (@bertrandtombal) 's Twitter Profile Photo

Thomas Zilli presenting the first results of EORTC 1414 "PEGASUS" at #EMUC24 EORTC. Another proof that GNRH antagonists induce fewer CV events in patients with CV history than agonists. Thanks also to D. Böhmer and P. Lara.

<a href="/ZilliThomas/">Thomas Zilli</a> presenting the first results of EORTC 1414 "PEGASUS" at #EMUC24 <a href="/EORTC/">EORTC</a>. Another proof that GNRH antagonists induce fewer CV events in patients with CV history than agonists. Thanks also to D. Böhmer and P. Lara.
European Association of Urology (EAU) (@uroweb) 's Twitter Profile Photo

#EMUC24: Congratualtions to T. Zilli, Bellinzona (CH) for his award winning abstract: "Irradiation + long-term adjuvant androgen deprivation with GnRH antagonist vs. GnRH agonist in pts with very high risk localised or locally advanced PCa: the EORTC GUCG-1414 phase 3 PEGASUS"

#EMUC24: Congratualtions to T. Zilli, Bellinzona (CH) for his award winning abstract: 

"Irradiation + long-term adjuvant androgen deprivation with GnRH antagonist vs. GnRH agonist in pts with very high risk localised or locally advanced PCa: the EORTC GUCG-1414 phase 3 PEGASUS"
French Journal of Urology (@p_urol) 's Twitter Profile Photo

Congrats Thomas Zilli and to all sub investigators of the PEGASUS trial Again a crucial message on preventing new #CV event in patients with past history of #cardiovasculardisease tombal